Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients

European Journal of Haematology

Volumn 79, Issue 5, 2007, Pages 371-381

  Abdalla, Amir Osman ^a,b   Hansson, Lotta ^a,b   Eriksson, Ingrid ^a,b   Näsman Glaser, Barbro ^a,b   Mellstedt, Håkan ^a,b   Österborg, Anders ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Idiotype vaccination; Long term Id vaccination; Myeloma; T cells

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN IDIOTYPE; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA;

ACTIVE IMMUNIZATION; ADULT; AGED; ARTICLE; BONE MARROW; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; MALE; MULTIPLE MYELOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

AGED; AGED, 80 AND OVER; BONE MARROW; CANCER VACCINES; CELL PROLIFERATION; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN IDIOTYPES; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PHENOTYPE; POLYMERASE CHAIN REACTION; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES; TIME FACTORS;

EID: 35048827110     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00962.x     Document Type: Article

References (47)

1. Durie BG, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003 4 : 379 98.
2. Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol 1987 87 : 342 55.
3. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998 91 : 3 21.
4. Bendandi M. Clinical benefit of idiotype vaccines: too many trials for a clever demonstration. Rev Recent Clin Trials 2006 1 : 67 74.
5. Hansson L, Abdalla AO, Moshfegh A, Choudhury A, Rabbani H, Nilsson B, Osterborg A, Mellstedt H. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res 2007 13 : 1503 10.
6. Inoges S, Rodriguez-Calvillo M, Zabalegui N, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 2006 98 : 1292 301.
7. Dabadghao S, Bergenbrant S, Anton D, He W, Holm G, Yi Q. Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. Br J Haematol 1998 100 : 647 54.
8. Hansson L, Rabbani H, Fagerberg J, Osterborg A, Mellstedt H. T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. Blood 2003 101 : 4930 6.
9. Wang RF. Immune suppression by tumor-specific CD4(+) regulatory T-cells in cancer. Semin Cancer Biol 2005 16 : 73 9.
10. Abdalla AO, Hansson L, Eriksson I, Nasman-Glaser B, Rossmann ED, Rabbani H, Mellstedt H, Osterborg A. Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma - evaluation of T-cell responses by different read-out systems. Haematologica 2007 92 : 110 4.
11. Keilholz U, Martus P, Scheibenbogen C. Immune monitoring of T-cell responses in cancer vaccine development. Clin Cancer Res 2006 12 : 2346s 52s.
12. Berger TG, Haendle I, Schrama D, et al. Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells. Int J Cancer 2004 111 : 229 37.
13. Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci U S A 2002 99 : 13009 13.
14. Yamshchikov GV, Barnd DL, Eastham S, et al. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int J Cancer 2001 92 : 703 11.
15. Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 2003 198 : 1753 7.
16. Bendandi M. The role of idiotype vaccines in the treatment of human B-cell malignancies. Expert Rev Vaccines 2004 3 : 163 70.
17. Coscia M, Kwak LW. Therapeutic idiotype vaccines in B lymphoproliferative diseases. Expert Opin Biol Ther 2004 4 : 959 63.
18. Choudhury A, Mosolits S, Kokhaei P, Hansson L, Palma M, Mellstedt H. Clinical results of vaccine therapy for cancer: learning from history for improving the future. Adv Cancer Res 2006 94 : 147 202.
19. Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, Ruden U, Lefvert AK, Holm G, Mellstedt H. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 1998 91 : 2459 66.
20. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975 36 : 842 54.
21. Rezvany M, Jeddi-Tehrani M, Österborg A, Kimby E, Wigzell H, Mellstedt H. Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen in CD4 T-cell subset. Blood 1999 94 : 1063 9.
22. Bergenbrant S, Yi Q, Osby E, Osterborg A, Ostman R, Bjorkholm M, Holm G, Lefvert AK. Anti-idiotypic B lymphocytes in patients with monoclonal gammopathies. Scand J Immunol 1994 40 : 216 20.
23. Osterborg A, Yi Q, Bergenbrant S, Holm G, Lefvert AK, Mellstedt H. Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests. Br J Haematol 1995 89 : 110 6.
24. Schwartz A, Fernandez Repollet E, Vogt R, Gratama JW. Standardizing flow cytometry: construction of a standardized fluorescence calibration plot using matching spectral calibrators. Cytometry 1996 26 : 22 31.
25. Zenger VE, Vogt R, Mandy F, Schwartz A, Marti GE. Quantitative flow cytometry: inter-laboratory variation. Cytometry 1998 33 : 138 45.
26. BDTM Cytometric Bead Array (CBA) 2003) Human Th1/Th2 Cytokine Kit Instruction Manual. BD Biosciences Pharmingen, San Diego.
27. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987 162 : 156 9.
28. Abdalla AO, Kiaii S, Hansson L, Rossmann ED, Jeddi-Tehrani M, Shokri F, Osterborg A, Mellstedt H, Rabbani H. Kinetics of cytokine gene expression in human CD4+ and CD8+ T-lymphocyte subsets using quantitative real-time PCR. Scand J Immunol 2003 58 : 601 6.
29. Fan J, Nishanian P, Breen EC, McDonald M, Fahey JL. Cytokine gene expression in normal human lymphocytes in response to stimulation. Clin Diagn Lab Immunol 1998 5 : 335 40.
30. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999 5 : 1171 7.
31. Rasmussen T, Hansson L, Osterborg A, Johnsen HE, Mellstedt H. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 2003 101 : 4607 10.
32. Matzinger P. An innate sense of danger. Semin Immunol 1998 10 : 399 415.
33. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005 5 : 263 74.
34. Choi C, Witzens M, Bucur M, Feuerer M, Sommerfeldt N, Trojan A, Ho A, Schirrmacher V, Goldschmidt H, Beckhove P. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 2005 105 : 2132 4.
35. Alleva DG, Burger CJ, Elgert KD. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. J Immunol 1994 153 : 1674 86.
36. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005 115 : 3623 33.
37. Orentas RJ, Kohler ME, Johnson BD. Suppression of anti-cancer immunity by regulatory T cells: back to the future. Semin Cancer Biol 2006 16 : 137 49.
38. Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 2006 16 : 115 23.
39. Mozaffari F, Hansson L, Kiaii S, Ju X, Rossmann ED, Rabbani H, Mellstedt H, Osterborg A. Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. Br J Haematol 2004 124 : 315 24.
40. Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Nishimura T. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 2004 95 : 697 703.
41. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005 54 : 721 8.
42. Yi Q, Osterborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert AK. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 1995 86 : 3043 9.
43. Frassanito MA, Cusmai A, Dammacco F. Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol 2001 125 : 190 7.
44. Tatsumi T, Kierstead L, Ranieri E, et al. Disease-associated bias in T helper type 1 (Th1)/Th2 Cd4+ T cell responses against MAGE-6 in HLA-DRB10401+ patients with renal cell carcinoma or melanoma. J Exp Med 2002 196 : 619 28.
45. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996 383 : 787 93.
46. Lauerova L, Dusek L, Simickova M, Kocak I, Vagundova M, Zaloudik J, Kovarik J. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 2002 49 : 159 66.
47. Aruga A, Aruga E, Tanigawa K, Bishop DK, Sondak VK, Chang AE. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol 1997 159 : 664 73.